Topic Listing for ARCA biopharma, Inc.

Acceleration Certain Events Acceptance Option Amendment
Acceptance Release Drug Product Accomplishments
Accomplishments 2005 Outlook Accomplishments Provides 2006 Outlook
Account Debtor Defined Code Such Additions Term Hereafter Accounting
Accounting Estimates Preparation Financial Statements Accounting Firm
Accounting Payment External Costs Internal Supplies Materials Accounting Standards Principles
Accounting Standards Updates Accrued Expenses
Accumulated Other Comprehensive Gain Loss Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Loss Ackground
Acquisition Fees Acute Peripheral Arterial Occlusion
Addition Developing Current Product Candidates Continue Evaluate Strategic Additional Clinical Trials
Additional Covenants Arca Additional Information Find
Additional Information Merger Find Additional Provisions
Administration Adopted 2009
Adopted Change Control Severance Benefit Plans Discourage Prevent Adopted Executive Change Control Severance Benefit Plan Discourage
Advertising Education Trademarks Advertising Promotional Standards
Affymetrix Aggregate Option Exercises 2004 Year-end Values
Aggregate Option Exercises 2005 Year-end Values Agreement
Agreement Plan Merger Reorganization Agreements Action
Agreements Bayer Alfimeprase
Alfimeprase Acute Ischemic Stroke Alfimeprase Acute Peripheral Arterial Occlusion
Alfimeprase Acute Peripheral Arterial Occlusion Pao Alfimeprase Catheter Occlusion
Alfimeprase Deep Venous Thrombosis Alfimeprase License Collaboration Agreements
Alfimeprase Stroke Alfimeprase Stroke Deep Venous Thrombosis
Allocations Between Base Salary Cash Bonus Equity Compensation Alteration Care Repair Liens
Amended Restated Addendum Employment Agreement Amended Restated Arca Biopharma Inc 2004 Equity Incentive
Amendment Amendment Agreement Plan Merger Reorganization
Amendment Exclusive License Agreement Amendment Lease
Amendment Restatement Bylaws Amendments
Amendments Articles Incorporation Bylaws Change Amendments Loan Agreement
Amgen Analytical Protocols Reports
Annual Cash Retainer Fees Annual Costs
Annual Financial Statements Audit Annual Reduction Expense Expected Approximately
Annual Report Form 10-k Available Information Annual Stock Option Grants
Anti-takeover Provisions Combined Charter Bylaws Prevent Frustrate Attempts Antibody Targets Program
Api Receipt Release Appendix
Appendix Assay List Appointment Cfo Coo
Appointment Grants Approved Fda Gencaro Entering Competitive Marketplace Not Succeed
Aptamers Arbitrator Dispute Resolution
Arc 183 Arc183
Arca Biopharma Arca Biopharma Appoints Kathryn Falberg Chief Financial Officer
Arca Biopharma Inc Arca Biopharma Inc Nasdaq Abio 2009
Arca Biopharma Inc Wishes Make Unrestricted Gifts University Arca Biopharma Receives Complete Response Letter Fda Gencaro
Arca Cannot Successfully Integrate Nuvelo Organization Not Able Arca Core Values
Arca Currently Pursuing Strategic Transaction Such Potential Combination Arca Dependent Key Personnel Attract Retain Qualified Employees
Arca Discovery Inc Arca Discovery Inc Wishes Make Unrestricted Gifts University
Arca Encounters Difficulties Enrolling Patients Clinical Trials Delayed Arca Evaluating Whether Raise Additional Funds Through Public
Arca Expects Fund Commitment Through Monthly Payments 20167 Arca Expects Fund Commitment Through Monthly Payments 23917
Arca Expects Incur Significant Costs Integrating Companies Single Arca Expects Rely Contract Research Organizations Conduct Clinical
Arca Fails Identify License Acquire Other Products Product Arca Implemented Anti-takeover Provisions Discourage Prevent Delay Takeover
Arca Incurred Continue Incur Increased Costs Result Being Arca Limited Ability Access Sufficient Funding Through Private
Arca Manufacturing Capacity Puts Risk Lengthy Costly Delays Arca Merger Inc
Arca Need Significantly Increase Size Organization Experience Difficulties Arca Not Able Obtain Fda Approval Successfully Develop
Arca Not Able Successfully Develop Obtain Fda Approval Arca Not Achieve Projected Development Goals Time Frames
Arca Not Expect Pay Cash Dividends Accordingly Stockholders Arca Party Securities Litigation Defending Lawsuits Hurt Arcas
Arca Required Establish Direct Sales Force Unable Business Arca Strategy
Arca Subject Applicable Regulatory Approval Requirements Foreign Countries Arca Unable Establish Direct Sales Force Business Harmed
Arca Unable Obtain Acceptable Prices Adequate Reimbursement Third-party Arcas Clinical Trials Product Candidates Not Yield Results
Arcas Competitors Better Positioned Marketplace Thereby Successful Arca Arcas Existing Indebtedness Adversely Affect Financial Condition Prevent
Arcas Failure Establish Manage Distribution Network Products Delay Arcas Intellectual Property Rights Not Preclude Competitors Developing
Arcas Investments Marketable Debt Securities Subject Credit Risk Arcas Product Candidates Receive Regulatory Approval Arca Subject
Arcas Stock Price Expected Volatile Archemix
Archemix Nuvelo Close Phase Trial Thrombin Inhibitor Arc183 Arketing Ales Istribution Osts
Assessment Goodwill Impairment Assets
Assignment Assignment Assumption Agreement
Assignment Form Assistance Questions
Assumption Awards Certain Reorganizations Attention Chief Financial Officer
Audit Committee Audit Committee Report
Authorization Agreements Etc Authorization Purchase Sale Shares
Authorized Disclosure Authorized Shares
Automatic Mutual Termination Available Information
Avecia Avecia Biologics
Award Award Limits
Background Bank Payable
Bankruptcy Barry Zubrow Become Lead Independent Director Board-
Base Salary Basf
Basic Financial Information Reporting Basic Lease Information
Basis Presentation Basis Presentation Principles Consolidation
Basis Presentation Significant Accounting Policies Batch Disposition Roles Responsibilities
Bayer Bayer Healthcare
Because Not Yet Commercialized Drug Candidates Ability Develop Been Independently Developed Receiving Party Without Aid Application
Been Named Defendant Class Action Suits Defending Lawsuits Beneficial Owners Management
Beneficial Ownership Reporting Compliance Best Clinical Responses Genotype Groups
Best Trial Board Independence Corporate Governance
Board Observer Rights Bonuses
Bonuses Named Executive Officers Awarded 2007 Borrowing Arrangements
Bucindolol Patent Rights Build Diversified Pipeline Product Candidates
Bulk Hold Time Study Business Overview
Bylaw Amendment Reverse Stock Split Name Change Callida Genomics
Cancellation Fee Capital Equipment List
Capital Lease Obligations Capitalization Software Developed Internal
Capitalization Voting Rights Cardiodx Inc
Cardiovascular Pharmacology Engineering Consultants Llc Cpec Cardiovascular Product Portfolio
Cash Bonus Cash Burn
Cash Equivalents Cash Equivalents Marketable Securities
Cash Equivalents Marketable Securities Restricted Cash Equivalents Short-term Investments
Cash Equivalents Short-term Investments Restricted Cash Flows Operating Investing Financing Activities
Cash Provided Financing Activities Cash Provided Used Financing Activities
Cash Provided Used Investing Activities Cash Provided Used Operating Activities
Cash Used Investing Activities Cash Used Operating Activities
Cash Used Provided Investing Activities Catheter Occlusion
Ccepted Greed Centrifuge Characterization
Certain Budgetary Disputes Certain Federal Income Tax Information
Certain Relationships Related Transactions Certain Rights Reserved Landlord
Certificates Stock Transfer Certification
Chairman Emeritus George Rathmann Phd Retires Board- Change Control
Changes Directors Compensation Following Merger Changes Internal Control Over Financial Reporting
Changes Production Changes Registrants Certifying Accountant
Chief Executive Officers Compensation Cleaning Validation
Clinical Compound Clinical Results Dna Substudy
Clinical Trial Drug Manufacturing Accruals Clinical Trial Drug Manufacturing Expense Supplies Asset
Clinical Trial Drug Manufacturing Expenses Clinical Trials Alfimeprase Other Products Not Yield Results
Clinical Trials Drug Candidates Not Yield Results Enable Clinical Trials Not Yield Results Enable Obtain Regulatory
Clinical Trials Products Not Yield Results Enable Further Clinical Trials Products Not Yield Results Enable Obtain
Coagulation Cascade Proteins Collaboration
Collaboration Agreement Collaboration License Agreement
Collaboration Overview Management Collaborative Agreements
Collaborative Manufacturing Agreements Collateral Funding Notice
Combined Fails Obtain Additional Financing Unable Fund Operations Combined Need Significantly Increase Size Organization Experience Difficulties
Combined Not Able Successfully Develop Commercialize Arcas Lead Combined Stock Price Expected Volatile Market Common Drop
Commencement Conduct Initial Work Commercial Success Nuvelos Products Depend Ability Protect Intellectual
Commercial Success Products Depend Ability Protect Intellectual Property Commercial Success Products Dependent Ability Protect Intellectual Property
Commercial Supply Commercialization
Commercialization Alfimeprase Commercialization Phase
Commercialization Plan Budget Commercialization-related Definitions Calculations
Commercialize Hospital-based Products United States Commercialize Products United States
Commitment Limit Grants 2004 Plan 2006 2007 2008 Commitment Quality Research Development
Commitments Commitments Contingencies
Committed Equity Financing Facility Entered Kingsbridge Not Available Committed Equity Financing Facility Kingsbridge Currently Not Available
Committed Equity Financing Facility Kingsbridge Not Available Desire Committees Board Directors
Common Areas Services Common Stock
Common Stock 001 Common Stock Offering
Communications Related Investigational Drugs Compensation
Compensation Benefits Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Cost Allocation Compensation Tables
Competition Completion Merger Result Dilution Future Earnings Per Share
Compliance Laws Regulations Comprehensive Income Loss
Comprehensive Loss Comprehensive Loss Income
Concentration Risk Concentrations Credit Risk
Conclusion Conditions Closing
Conditions Obligation Investor Accept Draw Down Conference Call Information
Confidential Proprietary Information Confidentiality
Confidentiality Intellectual Property Confirmation Small Scale Process Characterisation
Consent Ernst Young Llp Independent Registered Public Accounting Consent Independent Registered Public Accounting Firm
Consequence Option Exercise Consequences Violations Code
Consideration Consolidated Statements Operations
Contact Contact Information Reporting Code Violations
Contacts Contents
Contract Revenue Contract Revenues
Contracts Loans Checks Deposits Contractual Obligations
Controls Procedures Conversion Preferred Stock
Convertible Promissory Notes Convertible Promissory Notes Warrants
Corporate Governance Role Compensation Committee Corporate Information
Costs Associated Exit Disposal Activities Costs Associated Merger Difficult Estimate Higher Expected Harm
Covenant Quiet Enjoyment Covenants
Covenants Nuvelo Cpec Llc Arca Discovery Inc
Creating Late-stage Cardiovascular Creating Late-stage Cardiovasucular Biotechnology
Creation Direct Financial Obligation Off-balance Sheet Arrangement Criteria Short Acting Characteristics Aptamers
Critical Accounting Policies Estimates Cumulative Effect Change Accounting Principle
Currently Dependent Parties Variety Functions Enter Future Arrangements Currently Dependent Parties Variety Functions Enter Future Collaborations
Cycle Times D-i
Damage Fire Theft Water Data Information Sharing
Date Time Place Default Remedies
Defending Against Claims Relating Improper Handling Storage Disposal Defense Party Claims
Deferred Income Taxes Deferred Stock Awards
Deferred Stock Unit Awards Defined Terms Invoked Definition Allowable Commercialization Expenses Order
Defined Terms Purposes Definitions
Definitions Capitalized Terms Used Not Defined Amendment Shall Definitive Agreement
Delaware Corporation Deliverables Inventions
Deltagen Demise Commencement
Dendreon Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Dependent Key Personnel Attract Retain Qualified Employees Collaborators
Description Business Description Purchase Plan
Determination Certain Accounting Terms Development Commercialization Discretion Nuvelo Shall Sole Full Control
Development Commercialization Licensing Agreement Development Commercialization Licensing Agreement Laboratory Corporation America Holdings
Development Compound Development Costs
Development Genotype-defined Heart Failure Population Development Other Products Take Require Regulatory Approval Before
Development Phase Development Pipeline
Development Products Development Products Take Require Regulatory Approval Before They
Development Stage Risks Liquidity Going Concern Development Update
Diagnostic Collaboration Option Agreement Diagnostic Collaboration Option Agreement Cardiodx Inc
Did Receive Notice Mail Regarding Internet Availability Proxy Director Compensation
Director Compensation Table Director Continuing Office Until Annual Meeting Stockholders 2010
Directors Directors Continuing Office Until Annual Meeting Stockholders 2006
Directors Continuing Office Until Annual Meeting Stockholders 2007 Directors Continuing Office Until Annual Meeting Stockholders 2008
Directors Continuing Office Until Annual Meeting Stockholders 2009 Directors Continuing Office Until Annual Meeting Stockholders 2010
Directors Continuing Office Until Annual Meeting Stockholders 2011 Directors Recommend Stockholders Vote Each Nominees Director Proposals
Disclosure Conflicts Interest Discussion Significant Matters Considered Before Voting Special Meeting
Dispute Resolution Disputes
Dividend Policy Djustment Xercise Rice Hares Ffect Rganic Hanges
Dministration Documents Incorporated Reference
Double Counting Drag-along Rights
Draw Down Terms Drug Product Development Clinical Supply Agreement Effective 28th
Drug Product Dissolution Assay Hplc Method Development Drug Product Recalls
Due Diligence Performance Duration Termination
Duration Termination Cancellation Earnings Releases
Ecitals Ecords Udits
Effect Termination Effect Termination Expiration Sublicenses Arca Agreement Shall Terminate
Effective 2009 Effectiveness Amendment Shall Deemed Effective Due Execution Delivery
Efinitions Egend
Either Party Terminate Agreement Notice Parties Unable Agree Elements Executive Compensation Program
Elements Nuvelos Executive Compensation Program Eligibility
Email Internet Electronic Communications Eminent Domain
Employee Intellectual Property Agreement Employee Stock Purchase Plan
Employees Employees Asked Read Sign Following Agreement Time Employment
Employment Employment Agreement Christopher Ozeroff
Employment Agreement Michael Bristow Employment Agreement Randall Laurent
Employment Agreement Richard Brewer Employment Agreements
Employment Severance Agreements Encounter Difficulties Enrolling Patients Clinical Trials Delayed Otherwise
Enforce Rights Enforcement Patent Rights
Enforcement Patents Collaboration Period Entitled Vote Record Date
Entry Material Definitive Agreement Entry Premises
Environmental Health Safety Epresentations Arranties Arent Erger
Epresentations Older Equal Opportunity Unlawful Harassment
Equipment Equipment Leasehold Improvements Capitalized Software
Equipment Leasehold Improvements Software Equity Awards
Equity Compensation Plan Information Equity Incentive Plan
Erm Ermination
Erms Onditions Estricted Tock Wards Erms Onditions Ptions
Erms Onditions Tock Ppreciation Ights Esearch
Estimates Evaluation Disclosure Controls Procedures
Even Approved Nuvelos Products Not Accepted Marketplace Nuvelo Even Approved Products Not Accepted Marketplace Able Generate
Exact Name Registrant Specified Charter Exclusive License Agreement Regents University Colorado
Exclusivity Obligations Lead Non-lead Execution
Executive Bonuses Executive Change Control Severance Benefit Plan
Executive Committee Members Executive Compensation
Executive Compensation Determination Procedures Policies Executive Officers
Exhibits Existing Indebtedness Adversely Affect Financial Condition Prevent Fulfilling
Exit Disposal Activities Expanding Operations Difficulties Managing Growth Disrupt Business
Experienced Leadership Capable Driving Value Explanatory
Extension Option Face Exposure Currency Fluctuations Transactions Denominated Foreign Currencies
Face Fluctuations Operating Results Face Heavy Government Regulation Disputes Relating Business Practices
Face Heavy Government Regulation Fda International Regulatory Approval Face Heavy Government Regulation Fda Regulatory Approval Products
Face Intense Competition Face Product Liability Exposure Potential Unavailability Insurance
Face Uncertainty Respect Coverage Pricing Third-party Reimbursements Health Face Uncertainty Respect Coverage Pricing Third-party Reimbursements Healthcare
Facilities Lease Agreement Facilities Lease Agreements
Facility Exit Charge Facility Exit Charges
Facility Exit Costs Fail Maintain Effective System Internal Controls Not Able
Fail Maintain Existing Collaborative Agreements Develop New Arrangements Fail Maintain Existing Licenses Collaborations Develop New Business
Fail Maintain Existing Licenses Collaborations Such Collaboration Bayer Fail Maintain Existing Licenses Develop New Collaborations Business
Fail Maintain Existing Third-party Arrangements Collaborative Agreements Develop Failure Complete Merger Adversely Affect Nuvelos Stock Price
Failure Establish Maintain Effective Internal Control Over Financial Fair Competition Antitrust
Fair Value Disclosures Fair Value Financial Instruments
Fair Value Other Financial Instruments Fda Approval Medical Devices
Fda International Regulatory Approval Lead Product Candidate Alfimeprase Fda International Regulatory Approval Nuvelos Products Uncertain
Fda International Regulatory Approval Products Uncertain Federal Regulatory Reforms Adversely Affect Arcas Suppliers Ability
Fees Expenses Outside Counsel Respect Regulatory Affairs Unrelated Fin
Financial Instruments Financial Results Provides 2008 Outlook
Financial Statements Financial Statements Exhibits
Financial Update Financing Activities
Financing Arrangements Financing Facilities
Find Voting Results Force Majeure
Forced Degradation Study Foreign Corrupt Practices Act Improper Payments
Foreign Currency Derivatives Foreign Currency Transactions Contracts
Foreign Exchange Risk Form 10-k
Form 10-q Form Acknowledgement Expansion Rent Commencement Date
Former Name Address Changed Since Last Report Formerly Known Nuvelo Inc
Formulation Development Formulation Development Manufacturing Protocols Reports
Forward Looking Statement Forward Looking Statements
Forward-looking Statements Fte Funding Nuvelo Shall Pay Archemix Minimum Hundred
Funding Date Credit Extension Account Borrower Shall Business Future Expenses
Future Product Revenues Reduced Imports Countries Arcas Candidates Future Sales Arcas Products Suffer They Not Accepted
Future Sales Common Stock Depress Market Price Future Sales Gencaro Suffer Marketplace Acceptance Negatively Affected
Future Sales Possibility Arcas Common Stock Depress Market Future Sales Possibility Common Stock Depress Market Price
Future Sales Possibility Nuvelos Common Stock Depress Market Gain Bargain Purchase
Gencaro Gencaro Approved Fda Require Companion Genetic Test Administered
Gencaro Test General
General Administrative Expenses General Consequences
General Diagnostics Committee General Information
Genomic Health President Kimberly Popovits Joins Nuvelo Board Geographic Data
Gifts Gratuities Gilead Sciences Inc Formerly Myogen
Glossary Terms Goodwill
Goodwill Other Long-lived Assets Impairment Assessments Goodwill Other Long-lived Assets-impairment Assessments
Governing Law Miscellaneous Government Compliance
Government Regulation Government University Rights
Grant License Grant Licenses Other Rights
Grant Rights Acceptance Grants Plan-based Awards
Greement Growth Capital Line
Growth Future Commercialization Guidance Key Milestones
Guidance Upcoming Milestones Hares Ubject Lan
Hazardous Materials Chemicals Patient Samples Business Disputes Relating Health Care Reform Measures Materially Adversely Affect Arcas
Health Safety Environment Heart Failure
Heart Failure Population Heavily Dependent Parties Manufacturing Variety Other Functions Including
Heavily Dependent Parties Variety Functions Including Clinical Trials Held 2005
Held 2006 Held 2007
Held 2008 Held 2009
Herefore Consideration Foregoing Premises Mutual Covenants Set Forth Holdings Previously Awarded Equity
Holly Wned Ubsidiaries Orp Householding Proxy Materials
Human Resources Identifying Potential Conflicts Interest
Ignature Age Impairment Disposal Long-lived Assets
Impairment Goodwill Implemented Anti-takeover Provisions Discourage Prevent Delay Takeover Even
Incentive Stock Option Agreement Incentive Stock Option Limitations
Incentive Stock Options Income Taxes
Increase Shares Available Issuance Plan Indemnification
Indemnification Directors Officers Indemnification Insurance
Indemnification Limitation Liability Indemnifications
Indemnity Agreement Indemnity Waiver
Index Information Notice
Infringement Party Rights Infringement Patents Trademarks Parties
Insider Trading Policy Insurance
Integrating Companies Divert Attention Arcas Management Away Operations Integrating Nuvelo Arca Divert Attention Combined Management Away
Intellectual Property Interaction Independent Auditor
Interactions Healthcare Professionals Interest Income Expense Net
Interest Income Net Interest Other Expense
Interest Other Income Interest Other Income Expense
Interest Other Income Expense Net Interest Rate Risk
Interlab Qualification Internal Investigations
Internal Revenue Code 162 Internet Voting
Introduction Inventions Confidentiality Publicity
Investments Marketable Debt Securities Subject Credit Risk Adversely Investor Right Refusal
Investor Rights Agreement Investor Rights Agreement Related Financing Documents
Involvement 2005 Magazine Nuvelo Held Violation Securities Act Irst Mendment Ote Arrant Urchase Greement
Iscellaneous Iscellaneous Rovisions
Isposition Arrant Xercise Hares Issuer Purchases Equity Securities
Ithholding Itnesseth
Jill Pergande Vice President Human Resources Joint Steering Committee
Key Holder Shares Investor Kirin
Kirin Pharma Limited Labcorp Certain Party Suppliers Fail Supply Gencaro Test
Labcorp Certain Third-party Suppliers Fail Comply Ongoing Fda Labcorp Possesses Development Commercialization Capabilities Respect Laboratory Testing
Laboratory Corporation America Lack Marketing Commercialization Experience Biopharmaceutical Products Rely Parties
Lack Significant Marketing Commercialization Experience Biopharmaceutical Products Rely Landlords Base Building Work
Launch Plan Budget Lease
Lease Termination San Carlos Facility Lease Termination Sunnyvale Facility
Lease Termination Warrant Purchase Agreement Leg Attack
Legal Matters Legal Proceeding
Legal Proceedings Legend
Letters Credit Leukemia Therapeutic Antibody Program
Leverage Expertise Cardiovascular Disease Advance Clinical Development Programs Leverage Expertise Cardiovascular Disease Oncology Advance Clinical Development
Leverage Expertise Cardiovascular Disease Other Debilitating Medical Conditions Levys Agreement
License Agreement License Collaboration Agreement
License Grants Exclusivity License Sublicense Agreement Cpec Llc
Licenses Warranties Licensing Partnership Obligations
Licensing Patent Rights Light Arcas Capital Needs Current Resources Substantial Doubt
Ligibility Ward Imitations Limit Grants 2004 Plan 2006 2007 2008
Limitation Amendment Limitation Amendments
Limitation Liability Waiver Subrogation Limitations Disposition Legends
Limitations Effectiveness Controls Limitations Transfer Beneficiaries
Line Draw Period Time Effective Date Through 2008 Liquidity
Liquidity Capital Resources Liquidity Concentration Risk
List List Common Holders
List Contacts List Investors
List Key Holders List Subsidiaries
Loan Security Agreement Long-lived Assets Impairments
Loss Continuing Operations Loss Rights Market Key Products Significantly Impair Arcas
Loss Sale Assets Loves Agreement
Management Bonus Amounts Named Executive Officers 2005 Managements Discussion Analysis
Managements Report Internal Control Over Financial Reporting Managing Underwriters
Manufacture Sale Arcas Products Infringe Intellectual Property Rights Manufacture Sale Nuvelos Products Infringe Intellectual Property Rights
Manufacture Sale Products Infringe Intellectual Property Rights Others Manufacture Supply
Manufacturing Manufacturing Agreement Patheon Inc
Manufacturing Product Supply Manufacturing Validation
Market Opportunity Market Symbol Abio
Marketing Sales Material Abi Agreements
Material Weaknesses Exist Combined Reports Effectiveness Internal Control Maximum Liability Event Cardiodx Liable Arca Amount Excess
Medical Devices Related Gencaro Such Test Cause Contribute Medical Devices Related Gencaro Such Test Future Subject
Mendment Mendment Ermination Lan
Merge Acquire Other Companies Drug Candidates Failure Receive Merge Acquire Other Companies Failure Receive Anticipated Benefits
Merger Arca Biopharma Inc Merger Arca Nuvelo
Merger Exchange Ratio Reverse Stock Split Merger Nuvelo Inc
Merger Transaction Merger Transaction Costs
Merger Variagenics Inc Message Ceo
Method Development Method Evaluation
Method Transfer Method Validation Phase Levels
Microbiology Miscellaneous
Miscellaneous Provisions Modifications
Mortgages Assignments Subleases Transfers Tenants Interest Mutual Authority
Name Person Filing Proxy Statement Other Registrant Napa-2
Nasdaq Letter Nasdaq Listing Requirement
Ndemnification Imitation Iability 141 Indemnification Near-term Success Dependent Lead Product Candidate Alfimeprase
Near-term Success Dependent Lead Product Candidate Alfimeprase Cannot Necessary Consummate Transaction
Need Raise Additional Capital Such Unavailable Not Available Negotiable Certificates Deposit
Net Income Loss Net Income Loss Per Share
Net Loss Net Loss Per Share
Net Operating Loss Carryforwards New 1210 Hereby Added Loan Agreement Proper Numerical
New Hereby Inserted Loan Agreement Proper Numeric Order New Plan Benefits
New Schedule Hereby Attached Loan Agreement Form Amendment Nominating Corporate Governance Committee
Nominees Election Board Directors Three-year Term Ending 2008 Nominees Election Board Directors Three-year Term Ending 2009
Nominees Election Board Directors Three-year Term Ending 2010 Nominees Election Board Directors Three-year Term Ending 2011
Nominees Election Board Directors Three-year Term Ending 2012 Non-compete Agreement
Non-compete Exclusivity Obligations Non-exclusivity Rights
Non-stockholder Approved Equity Arrangements Nonqualified Stock Option Agreement
Nonstatutory Stock Options Indexed Not Able Develop Commercialize Drug Candidates Successfully
Not Able Develop Commercialize Lead Product Candidate Alfimeprase Not Achieve Projected Development Goals Time Frames Announce
Not Been Profitable Anticipate Continuing Losses Never Become Not Intend Pay Cash Dividends Common Stock Foreseeable
Not Receive Benefits Lost Potential Income Result Sale Not Yet Commercialized Drug Candidates Ability Commercialize Products
Not Yet Commercialized Drug Candidates Ability Develop Subsequently Notes
Notes Consolidated Financial Statements Notice Date Meaning Set Forth 116 Period
Notice Delivery Pledged Notice Exercise
Notice Grant Stock Option Notice Option Amendment
Notices Certain Transactions Notices Certificates
Now Therefore Parties Agree Follows Definitions Nu172
Nu206 Number 000-22873
Nuvelo Nuvelo 2004 Equity Incentive Plan
Nuvelo 401 Plan Nuvelo Adopted Change Control Severance Benefit Plans Discourage
Nuvelo Announces Pricing Common Stock Offering Nuvelo Announces Proposed Public Offering Common Stock
Nuvelo Appoints Ted Love Chairman Board Nuvelo Arca Executive Officers Directors Interests Different Addition
Nuvelo Arca Expect Incur Significant Costs Integrating Companies Nuvelo Arca Not Able Complete Merger Elect Pursue
Nuvelo Arca Not Expect Combined Pay Cash Dividends Nuvelo Arca Not Successful Integrating Organizations Combined Able
Nuvelo Bayer Healthcare Announce Phase Trials Alfimeprase Patients Nuvelo Board Directors Determined Believes Approval Amendment Nuvelos
Nuvelo Dependent Key Personnel Attract Retain Qualified Employees Nuvelo Encounters Difficulties Enrolling Patients Clinical Trials Delayed
Nuvelo Executive Change Control Severance Benefit Plan Applicable Nuvelo Executive Officers-potential Payments Termination Change Control
Nuvelo Face Fluctuations Operating Results Nuvelo Faces Heavy Government Regulation Disputes Relating Business
Nuvelo Faces Intense Competition Nuvelo Faces Product Liability Exposure Potential Unavailability Insurance
Nuvelo Fails Maintain Existing Licenses Develop New Collaborations Nuvelo Heavily Depends Parties Manufacturing Variety Other Functions
Nuvelo Host Conference Call Webcast Today 830 Eastern Nuvelo Implemented Anti-takeover Provisions Discourage Prevent Delay Takeover
Nuvelo Inc Nuvelo Inc Base Salaries Named Executive Officers Effective
Nuvelo Inc Base Salary Named Executive Officer Effective Nuvelo Need Raise Additional Capital Such Unavailable Needs
Nuvelo Not Able Develop Commercialize Nuvelos Product Candidates Nuvelo Not Achieve Projected Development Goals Time Frames
Nuvelo Not Intend Pay Cash Dividends Common Stock Nuvelo Not Yet Commercialized Product Candidates Nuvelos Ability
Nuvelo Party Securities Litigation Defending Lawsuits Hurt Nuvelos Nuvelo Receives Nasdaq Notification
Nuvelo Reports 2005 Financial Results Accomplishments Nuvelo Reports 2006 Financial Results Accomplishments
Nuvelo Reports 2007 Financial Results Nuvelo Reports 2008 Financial Results
Nuvelo Resumes Development Alfimeprase Multiple Blood-clot Related Indications Nuvelo Safe Harbor
Nuvelo Secures Committed Equity Financing Facility Nuvelo Significant Accumulated Deficit Anticipates Continuing Losses
Nuvelo Subject Risk Natural Disasters Nuvelos Business Prior Merger
Nuvelos Clinical Trials Product Candidates Not Yield Results Nuvelos Compensation Discussion Analysis
Nuvelos Investments Marketable Debt Securities Subject Credit Risk Nuvelos Stock Price Historically Been Likely Remain Highly
Nuvelos Success Dependent Proper Management Current Future Business Objectives Compensation Program
Objectives Nuvelos Compensation Program Off-balance Sheet Arrangements
Officers Offices
Ompliance Ecurities Once Project Been Awarded Patheon Detailed Budget Presented
Onditions Recedent Bligation Ompany Onditions Recedent Bligations Arent Erger
Onfidentiality Ongoing License
Operating Leases Opportunistically Seek License Acquire Complementary Products
Opportunistically Seek License Acquire Complementary Products Technologies Opt-in License
Opting Back Development Commercialization Opting Out Development Stage
Option Exercises Stock Vested Table Option Extend Term
Option Grants 2004 Option Grants 2005
Option Plan Benefits Organization
Organization Summary Significant Accounting Policies Ost Aunch Roduct Xpenses
Ote Arrant Urchase Greement Other Elements Executive Compensation Program
Other Enforcement Other Events
Other Income Other Information
Other Matters Meeting Other Potential Indications Gencaro
Other Powers Responsibilities Otherwise Prosecuted Filed Maintained
Outlook Outstanding Equity Awards Year-end
Ovenants Orporation Overview
Overview Combined Overview Nuvelos Executive Compensation Program
Ownership Ownership Arcas Common Stock Highly Concentrated Prevent Other
Packaging Validation Parachute Payments
Parking Part
Part Financial Information Part Legal Terms Conditions
Part Other Information Participants Solicitation
Parties Parties Date
Parties Own Control Patents Patent Applications Arca Required Partnering
Partnering Costs Meaning Given Financial Appendix Party Licenses
Party Securities Litigation Defending Lawsuits Hurt Business Volatility Party Securities Litigation Shareholder Derivative Suit Defending Lawsuits
Patent Applications Patent License Agreement
Patent License Assets Patent Prosecution Maintenance
Patent Right Patents
Patents Costs Enforcement Patents Licenses
Patents Trade Secrets Patheon Proposal Arc-fym1-0800-0406-r5
Payment Currency Payment Exercise Price
Payment Funding Options Opted-out Party Payment Interest Credit Extensions
Payment Purchase Price Purchaser Shall Delivered Check Transfer Payment Terms
Payments Payments Connection Change Control
Payments Development Compounds Licensed Products Archemix Exercises Profit Payments Development Compounds Licensed Products Archemix Not Exercised
Performance Awards Performance Milestones
Performance Restricted Stock Units Awards Pharmaceutical Division Kirin Brewery Ltd
Pharmacogenomics Phase
Piggyback Registration Rights Plan Benefits
Plan History Notes Plan Relocate Corporate Headquarters 2005 Result Disruptions Business
Political Contributions Activities Power Attorney
Pre-approval Process Policy Preferred Stock
Premarket Approval Drugs Premises
Presentation Partnering Agreement Choice Opting Out Staying Financial Press Release
Process Standards Process Validation
Product Liability Lawsuits Successfully Brought Against Arca Then Product Pipeline
Product Profile Discontinues Alfimeprase Development Product Profit Loss Allocation
Products Infringe Intellectual Property Rights Others Face Costly Products Not Accepted Marketplace Able Generate Significant Revenue
Programme Amendment Order Programs Expected Yield Nearest-term Proof-of-concept Data
Project Initiation Project Steering Committee Members
Projected Date Commercial Launch Territory Drug Product Platform Proof Concept Achieved Companies Actively Pursuing Optimized Generation
Property Equipment Property Equipment Net
Proposal Amendment Nuvelo Inc 2004 Equity Incentive Plan Proposal Amendment Restatement Nuvelo Inc 2004 Equity Incentive
Proposal B242201 Nuvelo Inc Proposal Election Board Directors
Proposal Ratification Selection Independent Registered Public Accounting Firm Proposed Merger Arca Biopharma Inc
Prosecution Protein Sequence Alfimeprase
Prototype Manufacturing Proxy Card
Proxy Properly Executed Voted Manner Directed Herein Undersigned Proxy Statement Prospectus Consent Solicitation Supplement Not Offers
Prudent Actions Plan Fiduciaries Ption Option Exercise
Public Communications Accuracy Reports Publications
Purchase Common Stock Purchase Equipment
Purchase Mechanics Purchase Plan Benefits
Purchase Sale Common Stock Purchase Stock
Purposes Nuvelo Special Meeting Pursuant 253 General Corporation Law
Pursuant Merger Agreement Arca Biopharma Put Option
Qcmd Manufacturing Compliance Quality Assurance
Quantitative Qualitative Disclosures Market Risk Quarterly Financial Statements
Quorum Requirements Quorum Voting Requirements
Ransfers Nvestors Ransfers Ommon Older
Reasonably Update Non-lead Terms Being Negotiated Prospective Party Reasons Amendment
Receivable Receive Information Plan Benefits
Receive Proxy Card Recent Accounting Pronouncements
Recent Accounting Pronouncements Impact Future Financial Position Results Recent Corporate Accomplishments
Recitals Reclassification
Recommendation Nuvelo Board Directors Records
Records Audit Rights Reduction Force
Reference Standards Drug Substances Related Reflecting Change Commercial Strategy
Registrants Telephone Number Including Area Code Registration Procedures
Registration Rights Registration Rights Agreement
Registration Rights Investor Applicable Covenant Agree Follows Registration Rights Voting
Regulatory Affairs Regulatory Approval Assistance Submissions
Regulatory Strategy Related Merger
Release Release Agreement
Relocated Corporate Headquarters 2005 Result Disruptions Business Loss Remainder Financial Appendix Provides Defined Accounting Terms Invoked
Remainder Page Intentionally Left Blank Remainder Page Intentionally Left Blank Signature Follows
Remainder Provides Definitions Defined Terms Invoked Marketing Sales Reorganization
Repayment Bank Payable Report
Report Ernst Young Llp Independent Registered Public Accounting Report Independent Registered Public Accounting Firm
Report Kpmg Llp Independent Registered Public Accounting Firm Reporting Reconciliation
Reporting Violations Code Reports Records Audits
Representations Warranties Representations Warranties Certain Covenants
Representations Warranties Covenants Representations Warranties Covenants Investor
Representations Warranties Purchaser Required Vote Board Directors Recommendation
Research Research Development
Research Development Collaborations Research Development Expenses
Research Licenses Research Programs
Reserved Resources Execute Strategy
Respect Dismissal Prejudice Arbitration Each Party Bear Own Respective Boards Directors Parent Each Approved Amendment Greement
Responsibilities Responsibilities Delivery Shipment Manufactured Api
Restricted Cash Restricted Stock Awards
Restricted Stock Units Restrictions Transfer
Restructuring Restructuring Expense
Restructuring Expenses Results Operations
Results Operations Financial Condition Results Provides 2007 Outlook
Retaliation Revenue Concentration Data
Revenue Recognition Reverse Split Ratio
Reverse Stock Split Revoke Proxy Shares Registered Name Stockholder Record
Revolving Maturity Date 2007 Limitation Amendments Right Co-sale
Right Refusal Co-sale Agreement Rights Refusal
Risk Factors Risks Related Arcas Financial Condition
Risks Related Intellectual Property Other Legal Matters Rnapc2
Rohibited Ransfers Royalties
Royalties Payments Nuvelo Products Archemix Royalty Report
Royalty Table Safe Harbor Statement
Salaries Sale Callida Segment
Sarbanes-oxley Act 2002 Schedule
Schedule Investors Schedule Purchasers
Scientific Industry Background Scope Statement
Secreted Proteins Program Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Securities Exchange Act 1934
Securities Exchange Act 1934 Amendment Securities Insider Trading
Securities Not Registered Securities Registered Pursuant Exchange Act
Security Ownership Certain Beneficial Owners Management Following Merger Seeking Help Information
Segment Data Segment Information
Segment Revenue Concentration Data Segments
Selection Independent Auditors Selection Independent Registered Auditors
Selection Independent Registered Public Accounting Firm Selling General Administrative Expenses
Series Redeemable Convertible Preferred Stock Severance Benefit Plan
Shares Common Stock Grant Shall Vest Records Shares Held Street Name Attend Annual Meeting
Shares Registered Name Broker Bank Beneficial Owner Shares Registered Name Stockholder Record
Shares Voted Grant Proxy Sharing Data
Signage Signature
Signature Page Follows Signatures
Significant Accounting Policies Significant Accumulated Deficit Anticipate Continuing Losses
Sonoma-2 Sources Uses Capital
Space Intentionally Left Blank Stability
Stablishment Urpose Erm Lan Stage 15l Fermentation Runs
Stage Assay Transfer Stage Assay Transfer Validated Methods
Stage Assay Validation Stage Capital Equipment Specification Procurement
Stage Cgmp Development Batches 3000l Scale Stage Cgmp Preparation 3000l Scale
Stage Engineering Batch 3000l Scale Stage Fermentation Scale-up Centrifuge Trials 3000l Scale
Stage Laboratory Process Characterisation Lpc Stage Laboratory Scale Purification Runs
Stage Process Transfer Fit Stage Validation Batches 3000l Scale
Stage Validation Documentation Standard Assumption
State Delaware Statutory Contractual Rights Appraisal Similar Remedies Available Stockholders
Stock Appreciation Rights Stock Certificate
Stock Incentive Plan Stock Option Exercise Notice
Stock Option Modification Stock Option Plan
Stock Options Stock Performance Graph
Stock Plans Stock Price Historically Been Likely Remain Highly Volatile
Stock Purchase Agreement Stock Purchase Sale
Stock Split Stock-based Compensation
Stockholder Communications Board Directors Stockholder Meeting
Stockholder Proposals 2006 Annual Meeting Stockholder Proposals 2008 Annual Meeting
Stockholder Proposals 2009 Annual Meeting Stockholder Proposals 2010 Annual Meeting
Stockholder Record Revoke Proxy Stockholders
Strategy Subcription Agreement
Subject Risk Natural Disasters Sublicense Arca
Sublicensing Sublicensing Arca
Submission Matters Vote Security Holders Subscription Agreement
Subsequent Event Subsequent Events
Subsequent Overall Plan Indication Shall Only Approved Mutual Subsidiaries
Success Dependent Proper Management Current Future Business Operations Success Nuvelos Potential Products Research Preclinical Studies Not
Success Potential Products Pre-clinical Studies Not Guarantee Results Success Potential Products Research Pre-clinical Studies Not Guarantee
Success Potential Products Research Preclinical Studies Not Guarantee Successfully Develop Commercialize Lead Drug Candidate Alfimeprase
Such Series Preferred Stock Summary
Summary Compensation Table Summary Federal Income Tax Consequences
Summary Option Plan Summary Provisions Amendment Restatement
Summary Recent Amendments 2004 Plan Supply
Survival Rights System Suitability Test
Table Contents Tax Returns Payments
Telephone Voting Term
Term Meaning Set Forth Term Termination
Term Termination Bankruptcy Termination
Termination Agreement Termination Amendment
Termination Breach Termination Collaboration
Termination Default Termination Material Definitive Agreement
Termination Pending Arbitration Termination Separation Package
Termination Sunnyvale Operating Lease Terms Proposed Transaction
Thrombin Inhibiting Aptamer Thrombin Inhibitor Program
Time Stock Option Grants Trademark Copyright Licenses
Transactions Arcas Chief Science Medical Officer Chairman Transactions Related Parties
Transfer Analytical Methods Transfer Drug Product Fill Finish
Transfer Landlords Interest Transitioning Developmental Stage Require Successful Completion Number Steps
Triggering Events Accelerate Increase Direct Financial Obligation Ts23 1yn
United States University Colorado
University Colorado Materials Transfer Agreement University Colorado Research Grant
University Colorados License Equity Holdings Inc Unless Arca Able Generate Sufficient Product Revenue Continue
Unregistered Sales Equity Securities Unregistered Sales Equity Securities Proceeds
Upcoming Events Upcoming Milestones
Update Financial Guidance Update Financial Guidance Provided-
Updated Outlook 2008 Urrency Ains Osses
Uvelo Validation Documentation
Valuation Impairment Review Acquired In-process Research Development Variagenics Been Named Defendant Class Action Suit Defending
Volatility Market Price Securities Engender Class Action Litigation Vote
Vote Annual Meeting Vote Important
Vote Important Accordingly Please Sign Return Accompanying Proxy Vote Received Notices
Vote Received Notices Proxy Cards Vote Shares Filling Out Returning Notice Regarding Availability
Vote Shares Registered Name Broker Bank Beneficial Owner Vote Shares Registered Name Broker Bank Beneficial Stockholder
Vote Shares Registered Name Stockholder Record Voting Agreement
Voting Intentions Executive Officers Directors Recommendations Voting Mail
Voting Proposal Amendment Nuvelo Inc 2004 Equity Incentive Voting Proposal Amendment Nuvelo Inc Employee Stock Purchase
Voting Proposal Election Board Directors Voting Proposal Ratification Selection Independent Registered Public Accounting
Voting Proxy Voting Proxy Revoking
Voting Revocation Proxies Waiver
Waivers Code Warrant
Warrant Purchase Agreement Warrant Purchase Common Stock
Warrant Purchase Shares Common Stock Warranties Indemnifications Insurance
Warrants Warrants Series Redeemable Preferred Stock
Webcast Conference Call Scheduled Thursday 2008 830 Edt Webcast Held 430 Today-
What Purpose Annual Meeting What Quorum Requirement Annual Meeting
What Vote Required Each Proposal Witnesseth
Wnt Therapeutics Program Workletter Agreement
Workplace Violence Xecution Ersion
Xempt Ransfers Xercise Arrant
Xhibit Xhibit Ndex
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki